Corrona, LLC, has announced that it will change its company name to CorEvitas. It will also expand its offerings in European markets while continuing to provide high-quality data from its eight patient registries. These registries include data on rheumatoid arthritis, multiple sclerosis, and psoriasis from almost 500 worldwide sites in the US, Japan, and Canada. CorEvitas has also acquired HealthUnlocked, an online community that includes 1.4 million patients with a variety of chronic and acute diseases, as well as biosamples, and remains a leader in RWE (real world evidence).
According to CEO and Chairman Raymond Hill, “the CorEvitas name reflects over twenty years’ experience generating evidence on clinical effectiveness and safety of therapies. CorEvitas is uniquely positioned to answer important questions around newly-approved therapies with novel mechanisms of action, while innovating with patient-centric research.” He adds, “we could not have reached this point without the valuable partnership of our patients, investigator sites, scientific advisors, and patient advocacy groups.” Read more here.
(Source: CISION PR Newswire, 3/9/21)